https://sciex.com/content/SCIEX/na/us/en


Contaminants and Novel Approaches in Food Analysis

Feb 17, 2016 | Blogs, Food / Beverage | 0 comments

During RAFA 2015New Food Magazine hosted a roundtable (sponsored by SCIEX) to bring together experts with routine food testing backgrounds to discuss the latest industry trends, challenges, recent technological advances, and expectations of future laboratories.

Both Vincent Paez, Senior Director of Food Testing and Andre Schreiber, Technical Applications Manager from SCIEX were in attendance and contribute with their extensive experience of working with and supporting routine testing laboratories, as well as developing advanced workflows on the forefront of food safety. 

The roundtable began with a simple question, “In the next 10 years what key changes do you see happening in the food and beverage industry in terms of food analysis?” A detailed discussion followed which covered the aspects of commercial laboratory testing, university laboratory research, the rise of digital technologies and the simplification of processes – in particular, the importance of informatics.

If you are interested in learning more about what each of the speakers had to say we have embedded the full 51-minute roundtable for you to watch below. 

Be sure to leave a comment below and share your thoughts on the questions asked as part of the discussion, or raise any questions you would like to be included in future roundtables!

Also, if you’re interested in watching more from RAFA 2015, check out Andre’s seminar titled “Igniting Your Routine Testing Methods.”

 

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial